EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$10.23 USD
+0.16 (1.59%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $10.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
EYPT 10.23 +0.16(1.59%)
Will EYPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EYPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EYPT
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
EYPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say
Other News for EYPT
EyePoint Pharmaceuticals (EYPT): Chardan Capital Maintains "Buy" Rating | EYPT Stock News
EyePoint Pharmaceuticals (EYPT) Receives Updated Analyst Ratings | EYPT Stock News
Q2 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript
EyePoint price target raised by $1 at H.C. Wainwright, here's why
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference | EYPT ...